About panzyga®
What is panzyga®?
Panzyga® is a high purity 10% human normal intravenous immunoglobulin solution (IVIg) derived from donated human plasma.5 While panzyga® uses glycine as a stabilizer, its precisely developed formulation and resulting product profile allows for rapid infusion rates without compromising tolerability.1, 3-6 Although the mechanism of action of panzyga® in each specific indication is not fully elucidated, adequate doses of IVIg have been clinically shown to:
:quality(80))
Panzyga® Indications
Panzyga® is approved for use across a range of clinical indications, providing proven clinical evidence, experience and confidence to support healthcare professionals, patients and caregivers.
Panzyga® is indicated for both replacement therapy in patients with primary and secondary immunodeficiencies (PID, SID) and for immunomodulation in specific autoimmune and neurological disorders.5
:quality(80))
About panzyga®
Complimenting our Immunoglobulin Portfolio
Commitment
Panzyga® is part of our commitment which drives us to expand our treatment solutions for healthcare professionals and patients.
Experience
Panzyga® has been designed to deliver an optimal treatment experience based on efficacy, convenience of administration, safety and tolerability.1-4
Support
Panzyga® can make a difference for healthcare professionals, patients and caregivers by providing a range of support resources during the treatment journey. You can look to the future and beyond the condition with confidence.
:quality(80))
Easy and convenient
Panzyga® provides convenient and comfortable administration with the advantage of colour-coded vials, a range of vial and pack sizes and room temperature storage. This demonstrates our commitment and support to tailoring solutions for healthcare professionals, patients and caregivers.
:quality(80))
Join the Octapharma Science Hub
Explore Octapharma's educational resources, on demand sessions and the science around our new health solutions advancing human life.
:quality(80))
References
Borte M, et al. J Clin Immunol 2017;37:603–612;
Arbach O, et al. Transfus Med 2019; 29:48–54;
Cornblath DR, et al. Brain 2022;145:887–896;
Ochs HD, et al. Immunotherapy 2018;10:1193–1202;
Panzyga® Summary of Product Characteristics;
Mersich C, et al. Biologicals 2017;45:33–38;
Mattucci A, et al. Front Immunol 2015;5:690;
Dalakas MC. Neurotherapeutics 2021; 18:2397-2418.
This is an international website for Panzyga® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
If you wish to contact Octapharma please use the contact form on our corporate website www.octapharma.com.
